exhibit46






                                                                                         Exhibit 4.6                          DESCRIPTION OF THE REGISTRANT’S SECURITIES                          REGISTERED PURSUANT TO SECTION 12 OF THE                                SECURITIES EXCHANGE ACT OF 1934   As of March 27, 2020, Daré Bioscience, Inc. (the "Company," "we," "our" and "us") had one class of  securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”):  common stock, $0.0001 par value per share (“common stock”).   General  The following is a brief description of the rights of our common stock. The description is qualified in its  entirety by reference to, and should be read in conjunction with, our Restated Certificate of Incorporation  (as amended, "Certificate"), our Second Amended and Restated By-laws (as amended, "Bylaws"), and  the applicable provisions of the Delaware General Corporation Law (the "DGCL"). Our Certificate and  Bylaws are filed as exhibits to the Annual Report on Form 10-K of which this exhibit is a part. The Annual  Report is filed with the U.S. Securities and Exchange Commission and is publicly available. We  encourage you to read our Certificate, our Bylaws and the applicable provisions of the DGCL for  additional information.   Authorized Capital  We are authorized to issue up to 120,000,000 shares of common stock and up to 5,000,000 shares of  preferred stock, $0.01 par value per share (the “preferred stock”). As of March 27, 2020, no shares of  preferred stock are outstanding.   The issued and outstanding shares of common stock are duly authorized, validly issued, fully paid and  nonassessable.   Rights of Holders of our Common Stock  Dividend Rights. Subject to preferences that may apply to any then outstanding preferred stock, holders  of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our  board of directors out of legally available funds.   Voting Rights. Each holder of our common stock is entitled to one vote for each share on all matters  submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have  cumulative voting rights.    Liquidation Rights. In the event of our liquidation, dissolution or winding up, holders of our common stock  will be entitled to share ratably in the net assets legally available for distribution to stockholders after the  payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted  to the holders of any then outstanding shares of preferred stock.   No Preemptive Rights. Holders of our common stock have no preemptive, conversion, subscription or  other rights, and there are no redemption or sinking fund provisions applicable to our common stock.    Rights of Preferred Stock May be Senior to Rights of Common Stock. Our board of directors has the  authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in  one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights,  preferences and privileges could include dividend rights, conversion rights, voting rights, terms of  redemption, and liquidation preferences, any or all of which may be greater than the rights of the holders  of our common stock.   Anti-Takeover Effect Provisions  Certain provisions in our Certificate and in our Bylaws may have an anti-takeover effect, including:           Classified Board. We have a classified board of directors with three-year staggered terms, which  may delay the ability of stockholders to change the composition of a majority of our board of directors. 





 






        Number of Directors. The number of directors on our board of directors is established by our   board of directors, which may delay the ability of stockholders to change the composition of a majority of  our board of directors.           No Cumulative Voting. Our stockholders cannot cumulate their votes in the election of directors,  which limits the ability of minority stockholders to elect director candidates.           Filling of Vacancies. Our board of directors have the exclusive right to elect a director to fill any  vacancy or newly created directorship.           Removing Directors. A director may be removed only for cause and only by the affirmative vote of  at least 75% of the votes which all the stockholders would be entitled to cast in any annual election of  directors or class of directors.           Prohibition on Written Consent. Our stockholders are prohibited from acting by written consent,  which forces stockholder action to be taken at an annual or special meeting of our stockholders.           Calling Special Meetings. Special meetings of our stockholders may be called only by our board  of directors, the chairman of our board of directors or our chief executive officer, which may delay the  ability of our stockholders to force consideration of a proposal or to take action, including the removal of  directors.           Advance Notice Procedures. Stockholders must comply with the advance notice procedures in  our Bylaws to nominate candidates to our board of directors and to propose matters to be acted upon at a  stockholders’ meeting, which may discourage or deter a potential acquirer from soliciting proxies to elect  the acquirer’s own slate of directors or otherwise attempting to obtain control of us;           Supermajority Provisions. The affirmative vote of the holders of at least 75% of the votes which all  the stockholders would be entitled to cast in any annual election of directors or class of directors is  required to amend or repeal, or to adopt any provision inconsistent with, the provisions in our Certificate  that relate to, among other matters, the classification of our board of directors, the number of our  directors, the removal of our directors, the filling of vacancies on our board of directors, the prohibition on  our stockholders to act by written consent, and the calling of special meetings of our stockholders.           Bylaw Amendments. Our board of directors, by majority vote, may amend, alter or repeal our  Bylaws and may adopt new Bylaws. Our stockholders may not adopt, amend, alter or repeal our Bylaws  or adopt any provision inconsistent therewith, unless such action is approved, in addition to any vote   required by our Certificate, by the affirmative vote of holders of at least 75% of the votes that all the   stockholders would be entitled to cast in any annual election of directors or class of directors, and the   affirmative vote of holders of at least 75% of the votes that all the stockholders would be entitled to cast in   any annual election of directors or class of directors is required to amend or repeal, or to adopt any   provision inconsistent with, the foregoing. These provisions may inhibit the ability of an acquirer from   amending our Certificate or our Bylaws to facilitate a hostile acquisition and may allow our board of   directors to take additional actions to prevent a hostile acquisition.           Preferred Stock. Our board of directors can determine to issue shares of preferred stock and to   determine the price and other terms of those shares, including preferences and voting rights, without   stockholder approval, which could significantly dilute the ownership of a hostile acquirer.           Additional Authorized Shares of Capital Stock. The shares of authorized common stock and   preferred stock available for issuance under our Certificate could be issued at such times, under such   circumstances, and with such terms as to impede a change in control.    In addition, we are subject to Section 203 of the DGCL, which, subject to certain exceptions, prohibits a   Delaware corporation from engaging in any “business combination” with any “interested stockholder” for     4836-6943-7622, v. 1 





 






 three years following the date that such stockholder became an interested stockholder, unless: (i) before  such date, the board of directors of the corporation approved either the business combination or the  transaction that resulted in the stockholder becoming an interested stockholder; (ii) on consummation of  the transaction that resulted in the stockholder becoming an interested stockholder, the interested  stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the  transaction commenced, excluding for purposes of determining the number of shares outstanding those  shares owned (a) by persons who are directors and also officers and (b) by employee stock plans in  which employee participants do not have the right to determine confidentially whether shares held subject  to the plan will be tendered in a tender or exchange offer; or (iii) on or after such date, the business  combination is approved by the board of directors and authorized at an annual or special meeting of  stockholders, and not by written consent, by the affirmative vote of at least 66 2⁄3% of the outstanding  voting stock not owned by the interested stockholder.    The term "business combination" generally includes mergers or consolidations resulting in a financial  benefit to the interested stockholder. The term "interested stockholder" generally means any person,  other than the corporation and any direct or indirect majority-owned subsidiary of the corporation, who,  together with affiliates and associates, owns (or owned within three years prior to the determination of  interested stockholder status) 15% or more of the outstanding voting stock of the corporation.   Exclusive Forum  Our Bylaws provides that, unless we consent in writing to the selection of an alternative forum, the Court  of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and  exclusive forum for: (a) any derivative action or proceeding brought on behalf of the Company, (b) any  action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other  employee, agent or stockholder of the Company to the Company or the Company’s stockholders,  including, without limitation, a claim alleging the aiding and abetting of such a breach of fiduciary duty, (c)  any action asserting a claim arising pursuant to any provision of the DGCL, our Certificate or our Bylaws  or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (d) any  action asserting a claim governed by the internal affairs doctrine or other “internal corporate claim” as that  term is defined in Section 115 of the DGCL. Our Bylaws also provide that any person or entity purchasing  or otherwise acquiring or holding any interest in shares of our capital stock shall be deemed to have  notice of and consented to the foregoing.   Dissenters' Rights of Appraisal and Payment  Under the DGCL, with certain exceptions, our stockholders have appraisal rights in connection with a  merger or consolidation of the Company. Under the DGCL, stockholders who properly request and  perfect appraisal rights in connection with such merger or consolidation will have the right to receive  payment of the fair value of their shares as determined by the Delaware Court of Chancery.   Listing  Our common stock is listed on the NASDAQ Capital Market under the symbol “DARE.”   Transfer Agent and Registrar  The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company,  LLC.     4836-6943-7622, v. 1